• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Electromed Inc.

    9/30/25 4:15:49 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ELMD alert in real time by email
    DEFA14A 1 elmd20250925_defa14a.htm FORM DEFA14A elmd20250925_defa14a.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 14A

     

    PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Filed by the Registrant ☑

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☑

    Definitive Additional Materials

    ☐

    Soliciting Material Pursuant to §240.14a-12

     

     

    ELECTROMED, INC.
    (Name of Registrant as Specified in Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

    ☑

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

     



     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    image01.jpg

     

    ELECTROMED, INC.

    500 SIXTH AVENUE NW 

    NEW PRAGUE, MN 56071

     

     

     

     

     

     

     

     

     

    V78936-P37864

     

     image03.jpg

    image10.jpg

    Your Vote Counts! Electromed, Inc. 2025 Annual Meeting Vote by November 13, 2025 11:59 PM ET

     

    You invested in ELECTROMED, INC. and it’s time to vote!

    You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on November 14, 2025.

     

    Get informed before you vote 

    View The Annual Report on Form 10-K and Notice and Proxy Statement and Shareholder Letter online OR you can receive a free paper or email copy of the material(s) by requesting prior to October 31, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

     

             
       image04.jpg For complete information and to vote, visit www.ProxyVote.com  
           
      Control #  image05.jpg  
             

     

    Smartphone users

     

    Point your camera here and
    vote without entering a
    control number
      

     

     
    image07.jpg
    Vote Virtually at the Meeting*
    November 14, 2025
    8:00 AM CST
    image06.jpg

    Virtually at:
    www.virtualshareholdermeeting.com/ELMD2025

       
       
       

     

    *Please check the meeting materials for any special requirements for meeting attendance.

     

     

     

     

    Vote at www.ProxyVote.com

     


     

    THIS IS NOT A VOTABLE BALLOT

     

    This is an overview of the proposals being presented at the
    upcoming shareholder meeting. Please follow the instructions on
    the reverse side to vote these important matters.

     

    Voting Items     Board
    Recommends
    1. Election of Directors, thereby setting the number of directors at eight.  
      Nominees:      
      01) James L. Cunniff 05) Kathleen S. Skarvan
    check.jpg For
      02) Stan K. Erickson 06) Andrew J. Summers  
      03) Gregory J. Fluet 07) Kathleen A. Tune  
      04) Joseph L. Galatowitsch 08) Andrea M. Walsh  
         
    2. To ratify appointment of RSM US LLP as our independent registered public accounting firm.
    check.jpg For
    3. To approve, on a non-binding and advisory basis, our executive compensation.
    check.jpg For
    4. To recommend, on a non-binding advisory basis, whether executive compensation votes should occur every year, every two years or every three years.
    one.jpg Year
    NOTE: At their discretion, the proxies are authorized to vote on any other business properly brought before the meeting or any adjournment thereof. 1 Year

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

     

    V78937-P37864  

     

     
    Get the next $ELMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELMD

    DatePrice TargetRatingAnalyst
    8/27/2025$36.00Buy
    Lake Street
    7/22/2025$29.00Buy
    Roth Capital
    2/20/2025$38.00Buy
    B. Riley Securities
    More analyst ratings

    $ELMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Summers Andrew sold $1,598,454 worth of shares (65,714 units at $24.32) (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    9/12/25 4:13:36 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CEO and President Cunniff James L. covered exercise/tax liability with 1,291 shares and was granted 17,000 shares, increasing direct ownership by 12% to 147,751 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    9/4/25 4:12:25 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Nagel Bradley M. covered exercise/tax liability with 562 shares and was granted 5,300 shares, increasing direct ownership by 28% to 21,838 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    9/4/25 4:11:37 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Electromed, Inc. Announces Share Repurchase Authorization

    Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that on September 9, 2025, its Board of Directors authorized Electromed to repurchase up to $10.0 million of Electromed common stock. This follows the exhaustion of Electromed's most recent share repurchase authorization in the fourth quarter of fiscal 2025, as previously reported. The timing and amount of share repurchases, if any, will be determined by management based on its evaluation of market conditions and other considerations. Repurchases may be made from time to time on the open market at prevailing market prices, in privately negotiated transactions, in block trades

    9/9/25 9:00:00 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. Announces Record Fiscal 2025 Fourth Quarter and Full Year Financial Results

    Record quarterly and annual revenues and operating income, marking the eleventh consecutive quarter of year-over-year revenue and operating income growth Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ("Q4 FY 2025") and full year ended June 30, 2025 ("FY 2025"). Q4 FY 2025 Company Highlights Net revenue increased 17.3% to a record $17.4 million in Q4 FY 2025, from $14.8 million in the fourth quarter of the prior fiscal year. Operating income was a record $3.0 million, a 30.2% increase from the fourth quarter of the prior fiscal year. Net income was $2.2 million, or $0.25 p

    8/26/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. to Report Q4 Fiscal 2025 Financial Results on August 26, 2025

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2025 fourth quarter ended June 30, 2025, on August 26, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electromed Q4 FY 202

    8/12/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    SEC Filings

    View All

    SEC Form DEF 14A filed by Electromed Inc.

    DEF 14A - Electromed, Inc. (0001488917) (Filer)

    9/30/25 4:15:50 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEFA14A filed by Electromed Inc.

    DEFA14A - Electromed, Inc. (0001488917) (Filer)

    9/30/25 4:15:49 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Electromed, Inc. (0001488917) (Filer)

    9/9/25 9:00:09 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Cunniff James L. bought $137,250 worth of shares (9,000 units at $15.25), increasing direct ownership by 900% to 10,000 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    3/5/24 4:49:02 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Summers Andrew bought $302,368 worth of shares (28,797 units at $10.50) (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    12/18/23 4:44:26 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cunniff James L. bought $10,560 worth of shares (1,000 units at $10.56) (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    11/22/23 4:01:43 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street resumed coverage on Electromed with a new price target

    Lake Street resumed coverage of Electromed with a rating of Buy and set a new price target of $36.00

    8/27/25 8:41:37 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Roth Capital initiated coverage on Electromed with a new price target

    Roth Capital initiated coverage of Electromed with a rating of Buy and set a new price target of $29.00

    7/22/25 7:52:34 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    B. Riley Securities initiated coverage on Electromed with a new price target

    B. Riley Securities initiated coverage of Electromed with a rating of Buy and set a new price target of $38.00

    2/20/25 7:01:40 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Financials

    Live finance-specific insights

    View All

    Electromed, Inc. Announces Record Fiscal 2025 Fourth Quarter and Full Year Financial Results

    Record quarterly and annual revenues and operating income, marking the eleventh consecutive quarter of year-over-year revenue and operating income growth Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ("Q4 FY 2025") and full year ended June 30, 2025 ("FY 2025"). Q4 FY 2025 Company Highlights Net revenue increased 17.3% to a record $17.4 million in Q4 FY 2025, from $14.8 million in the fourth quarter of the prior fiscal year. Operating income was a record $3.0 million, a 30.2% increase from the fourth quarter of the prior fiscal year. Net income was $2.2 million, or $0.25 p

    8/26/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. to Report Q4 Fiscal 2025 Financial Results on August 26, 2025

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2025 fourth quarter ended June 30, 2025, on August 26, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electromed Q4 FY 202

    8/12/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. Schedules its Third Quarter Fiscal 2025 Financial Results Conference Call for May 13, 2025 at 5:00 p.m. ET

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2025 third quarter ended March 31, 2025, on May 13, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electromed Q3 Fiscal 2025

    4/29/25 8:30:00 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Leadership Updates

    Live Leadership Updates

    View All

    Electromed, Inc. to Join Russell 2000® and Russell 3000® Indexes

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Electromed is joining these important market indices, which serve as leading benchmarks for institutional investors and as the basis for numerous index-linked financial products," said Jim Cunniff, Electromed's President and Chief Executive Off

    5/27/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc., Appoints Peter Horwich, Vice President, Marketing

    Key hire will drive the Company's market development and therapy adoption initiatives Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Peter Horwich as Vice President, Marketing. Mr. Horwich, an accomplished marketing veteran, brings over 20 years of experience in driving commercial growth in the Medical Technology market to Electromed. Prior to joining Electromed, Horwich directed Global Strategic Marketing for Respiratory Therapies at Abiomed (now J&J MedTech), a Medical Device manufacturer of extracorporeal membrane oxygenation (ECMO) lung recovery systems, where he was responsible for global marketing

    10/28/24 8:30:00 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed Names Jim Cunniff as President and Chief Executive Officer

    Healthcare Executive Brings More Than 30 Years of Executive Experience and Commercial Success to Electromed Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Jim Cunniff as its new President and Chief Executive Officer (CEO), effective July 1, 2023. Mr. Cunniff will also join Electromed's Board of Directors. "We are pleased to announce the appointment of Jim Cunniff as president and CEO," said Lee Jones, Chair of the Board. "Jim is a proven executive with deep experience driving growth and profitability through excellence in products and services that benefit patients and support care teams. "As Kathle

    6/5/23 8:15:00 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Electromed Inc.

    SC 13D/A - Electromed, Inc. (0001488917) (Subject)

    11/21/24 4:09:11 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Electromed Inc.

    SC 13G/A - Electromed, Inc. (0001488917) (Subject)

    11/13/24 5:42:25 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Electromed Inc.

    SC 13G/A - Electromed, Inc. (0001488917) (Subject)

    11/12/24 4:09:16 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care